section name header

Pronunciation ⬇

be-si-FLOX-a-sin

Classifications ⬆ ⬇

Therapeutic Classification: anti-infectives

Pharmacologic Classification: Fluoroquinolones

Indications ⬆ ⬇

REMS


Action ⬆ ⬇

  • Inhibits bacterial DNA synthesis by inhibiting DNA gyrase.
Therapeutic effects:
  • Death of susceptible bacteria with decreased signs/symptoms and sequelae of bacterial conjunctivitis.

Spectrum:

Pharmacokinetics ⬆ ⬇

Absorption: Minimal absorption follows ophthalmic use.

Distribution: Unknown.

Metabolism/Excretion: Unknown.

Half-Life: 7 hr.

Time/Action Profile ⬆ ⬇

ROUTEONSETPEAKDURATION
Ophthunknownunknown6–12 hr



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

EENT: conjunctival redness, blurred vision, eye irritation, eye pain, eye pruritus.

Neuro: headache

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆

Besivance